All About Multiple Sclerosis

More MS news articles for June 2004

Biogen Idec, Elan file for European approval of new MS drug

June 4, 2004
Triangle Business Journal

Biogen Idec and Irish partner Elan Corp. have submitted a marketing authorization application to the European Medicines Agency for approval of their multiple sclerosis treatment Antegren.

The drug, which could reach the U.S. market by mid-2005, is being developed as a follow-up to Biogen Idec's top selling drug, Avonex, a multiple sclerosis drug produced at the company's Research Triangle Park facilities.

About 1 million people worldwide suffer from MS, which is a chronic nervous system disease.

Cambridge, Mass.-based Biogen Idec has more than 450 employees at its Research Triangle Park facilities.

Copyright © 2004, American City Business Journals Inc.